Retosiban
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Retosiban
- DrugBank Accession Number
- DB11818
- Background
Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 494.592
Monoisotopic: 494.252920211 - Chemical Formula
- C27H34N4O5
- Synonyms
- Retosiban
- External IDs
- GSK-221149
- GSK-221149A
- GSK221149A
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AOxytocin receptor modulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- N-piperazineacetamides / Alpha amino acids and derivatives / Indanes / 2,5-dioxopiperazines / 2,4-disubstituted oxazoles / N-alkylpiperazines / Morpholines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides show 8 more
- Substituents
- 1,4-diazinane / 2,4-disubstituted 1,3-oxazole / 2,5-dioxopiperazine / Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group show 23 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GIE06H28OX
- CAS number
- 820957-38-8
- InChI Key
- PLVGDGRBPMVYPB-FDUHJNRSSA-N
- InChI
- InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
- IUPAC Name
- (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione
- SMILES
- CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)C2=COC(C)=N2)C(=O)[C@H](NC1=O)C1CC2=CC=CC=C2C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11340891
- PubChem Substance
- 347828165
- ChemSpider
- 9515833
- BindingDB
- 50372608
- ChEMBL
- CHEMBL429736
- ZINC
- ZINC000006718496
- PDBe Ligand
- NU2
- Wikipedia
- Retosiban
- PDB Entries
- 6tpk
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Obstetric Labour, Premature 1 somestatus stop reason just information to hide 3 Terminated Treatment Obstetric Labour, Premature 2 somestatus stop reason just information to hide 2 Completed Treatment Obstetric Labour, Premature 1 somestatus stop reason just information to hide 1 Completed Basic Science Obstetric Labour, Premature 1 somestatus stop reason just information to hide 1 Completed Treatment Obstetric Labour, Premature 3 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.156 mg/mL ALOGPS logP 2.32 ALOGPS logP 1.84 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 10.88 Chemaxon pKa (Strongest Basic) 0.44 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 104.98 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 131.33 m3·mol-1 Chemaxon Polarizability 52.99 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0000900000-ed096914657c0c7525a7 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0110900000-cbd1d08342dc36b7975a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f6t-0242900000-9f83761afea6fe3a0d13 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000f-0062900000-177431f28a31de3a710c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0fdk-2952500000-142d78e1a9a02de5898e Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000j-6161900000-d50c82b09c340c419230 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 227.252217 predictedDarkChem Lite v0.1.0 [M-H]- 214.127 predictedDeepCCS 1.0 (2019) [M+H]+ 227.430117 predictedDarkChem Lite v0.1.0 [M+H]+ 216.0844 predictedDeepCCS 1.0 (2019) [M+Na]+ 226.952817 predictedDarkChem Lite v0.1.0 [M+Na]+ 221.95393 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsOxytocin receptor
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Modulator
- General Function
- Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system
- Specific Function
- Oxytocin receptor activity
- Gene Name
- OXTR
- Uniprot ID
- P30559
- Uniprot Name
- Oxytocin receptor
- Molecular Weight
- 42770.99 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at October 20, 2016 20:50 / Updated at August 27, 2024 19:15